{"url":"https://newsforagent.com/news/2026-10-22/molbio-diagnostics-fy26-revenue-growth","markdown_url":"https://newsforagent.com/news/2026-10-22/molbio-diagnostics-fy26-revenue-growth.md","title":"Molbio Diagnostics Posts Rs 1,446 Crore FY26 Revenue","headline":"Molbio Diagnostics FY26 Revenue Rises 41.7% to Rs 1,446 Crore as Test-Kit Volumes Climb","description":"Molbio Diagnostics reported FY26 revenue of Rs 1,446 crore, up 41.7%, with test-kit volumes at 17.6 million units and FY27 growth targeted at about 25%.","section":"Earnings & Results","published_at":"2026-10-22T02:03:39+00:00","modified_at":"2026-10-22T02:03:39+00:00","author":"News Desk","key_takeaways":["Molbio Diagnostics reported FY26 revenue of Rs 1,446 crore, up 41.7%, and net profit of Rs 164 crore, up 14.9%.","Test-kit volumes rose to 17.6 million units in FY26 from 8.8 million units in FY24.","Molbio has annual capacity for 39 million test kits and 5,400 Truenat devices, with FY26 utilisation at 58.25% and 42.30% respectively."],"companies":[{"name":"Molbio Diagnostics","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000dma/molbio-diagnostics","website":"http://www.molbiodiagnostics.com"}],"source":{"publisher":"NDTV Profit","title":"Molbio Diagnostics Has Spare Capacity. Can It Turn That Into Growth?","url":"https://www.ndtvprofit.com/business/molbio-diagnostics-has-spare-capacity-can-it-turn-that-into-growth-12217831"},"other_sources":[],"tags":["Earnings & Results","Molbio Diagnostics"],"body_markdown":"[Molbio Diagnostics](https://akta.pro/company-profiles/0000dma/molbio-diagnostics) reported FY26 revenue of Rs 1,446 crore, up 41.7% year on year, with test-kit volumes rising 41% to 17.6 million units. The company said net profit rose 14.9% to Rs 164 crore. Molbio makes the portable Truenat molecular testing platform and single-use test kits, and has installed more than 12,500 devices across over 90 countries.\n\n## Molbio's FY26 Results and Truenat Kit Volumes\n\nMolbio's revenue increased 41.7% year on year to Rs 1,446 crore in FY26, while net profit rose 14.9% to Rs 164 crore, [NDTV Profit](https://www.ndtvprofit.com/business/molbio-diagnostics-has-spare-capacity-can-it-turn-that-into-growth-12217831) reported. EBITDA increased 22.6% to Rs 328 crore, with an EBITDA margin of 22.6%. Test-kit sales reached 17.6 million units in FY26, up from 8.8 million units in FY24, a compound annual growth rate of 41%.\n\nTruenat is a portable, battery-operated, multi-disease real-time PCR platform that delivers results in about 60 minutes. The platform has been used to conduct more than 40 million tests worldwide. Consumables accounted for 74% of product revenue in FY26 and 75% in the first quarter of FY27. Tuberculosis test kits accounted for about 70.2% of FY26 revenue and 96% of test-kit sales volume.\n\nMolbio has annual manufacturing capacity for 39 million test kits and 5,400 Truenat devices. In FY26, capacity utilisation was 58.25% for test kits and 42.30% for devices. Management targets revenue growth of about 25% and an EBITDA margin of 24% to 25% for FY27. Annual Truenat device sales are expected to remain within the historical range of 2,200 to 2,600 units.\n\n## Molbio's HPV Test and AI Pathology Moves\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Molbio launched India's first indigenous WHO-IARC-validated HPV test, Truenat HPV-HR Plus, in June 2026, with 91.5% specificity and 80.4% sensitivity for cervical cancer screening. AIIMS New Delhi collaborated on validation of the test, and ICMR institutes participated in the study alongside WHO-IARC. In February 2026, Molbio launched BactoSiA, an AI-assisted TB treatment monitoring solution, at WHX Labs World Health Expo in Dubai.\n\n## Molbio's Stake Sales Before the Results\n\nIndia Business Excellence Fund III sold 30 lakh Molbio Diagnostics shares on September 23, 2026, reducing its stake from 11.52% to 8.92%, [ScanX](https://akta.pro/news-signals) reported. The fund sold a further 23,77,627 shares on September 30, 2026, cutting its stake to 6.85%. Kotak Mahindra Mutual Fund acquired 570,000 Molbio Diagnostics shares on October 8, 2026, raising its stake to 5.4834% of voting capital.\n\n## What Molbio Has Said About FY27\n\nMolbio is pursuing US Food and Drug Administration submissions for its products and has secured European Union In Vitro Diagnostic Regulation Class C certification for its Truenat CT/NG test kits. Management is working to strengthen its presence in Africa and Southeast Asia while preparing to enter Europe and the US.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}